PHGE has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PHGE has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
BiomX's change in receivables for the quarter that ended in Mar. 2024 was $0.00 Mil. It means BiomX's Accounts Receivable stayed the same from Dec. 2023 to Mar. 2024 .
BiomX's change in receivables for the fiscal year that ended in Dec. 2023 was $0.00 Mil. It means BiomX's Accounts Receivable stayed the same from Dec. 2022 to Dec. 2023 .
BiomX's Accounts Receivable for the quarter that ended in Mar. 2024 was $0.00 Mil.
Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. BiomX's liquidation value for the three months ended in Mar. 2024 was $-48.14 Mil.
The historical data trend for BiomX's Change In Receivables can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BiomX Annual Data | |||||||||||||||
Trend | Jun18 | Jun19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Change In Receivables | Get a 7-Day Free Trial | - | - | - | - | - |
BiomX Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Change In Receivables | Get a 7-Day Free Trial | - | - | - | - | - |
Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.
Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BiomX (AMEX:PHGE) Change In Receivables Explanation
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
BiomX's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:
Days Sales Outstanding | |||||
= | Accounts Receivable | / | Revenue | * | Days in Period |
= | 0 | / | 0 | * | 91 |
= |
2. In Ben Graham's calculation of liquidation value, BiomX's accounts receivable are only considered to be worth 75% of book value:
BiomX's liquidation value for the quarter that ended in Mar. 2024 is calculated as:
Liquidation Value | |||||||
= | Cash, Cash Equivalents, Marketable Securities | - | Total Liabilities | + | (0.75 * Accounts Receivable) | + | (0.5 * Total Inventories) |
= | 43.007 | - | 91.15 | + | 0.75 * 0 | + | 0.5 * 0 |
= | -48.14 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of BiomX's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.
Assaf Oron | officer: Chief Business Officer | C/O BIOMX LTD., 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002 |
Eddie Williams | director | 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080 |
Michael E. Dambach | director | 22 EINSTEIN STREET, FLOOR 4, NESS ZIONA L3 7414003 |
Jason M. Marks | director | C/O AMARIN PHARMA, INC., 440 US HIGHWAY 22, BRIDGEWATER NJ 08807 |
Carl L Gordon | 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Orbimed Israel Biofund Gp Limited Partnership | director, 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 1022-4629 |
Chidozie Ugwumba | 10 percent owner | 158 FILMORE STREET, DENVER CO 80206 |
Thomas Layton Walton | 10 percent owner | P.O. BOX 1860, BENTONVILLE AR 72712 |
Paul J Sekhri | director | C/O VEEVA SYSTEMS INC., 4637 CHABOT DRIVE, SUITE 210, PLEASANTON CA 94588 |
Lynne Marie Sullivan | director | C/O SOLID BIOSCIENCES, LLC, 141 PORTLAND STREET, FIFTH FLOOR, CAMBRIDGE MA 02139 |
Marina Wolfson | officer: Principal Financial Officer | C/O BIOMX LTD., 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002 |
Jonathan Eitan Solomon | director, officer: Chief Executive Officer | C/O BIOMX LTD., 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002 |
Alan Charles Moses | director | C/O 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002 |
Russell Greig | director | C/O MERUS N.V., YALELAAN 62, UTRECHT P7 3584 CM |
Gbolahan Amusa | director | 17 STATE STREET 21 FLOOR, NEW YORK NY 10004 |
From GuruFocus
By PRNewswire PRNewswire • 07-17-2019
By PRNewswire PRNewswire • 10-28-2019
By PRNewswire PRNewswire • 03-13-2019
By Marketwired Marketwired • 05-18-2021
By PRNewswire PRNewswire • 05-10-2019
By PRNewswire PRNewswire • 10-10-2019
By GuruFocus Research GuruFocus Editor • 07-30-2021
By Marketwired Marketwired • 08-12-2021
By PRNewswire PRNewswire • 07-28-2022
By PRNewswire PRNewswire • 10-23-2019
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.